Skip to content
    GILD
    Earnings call· Mar 2025(Q1 FY25)

    GILEAD SCIENCES Q1 FY25 earnings call GILD

    Apr 24, 2025 Source

    Executive summary

    Gilead Q1 FY25 — Strong Base Business Growth and Key Pipeline Progress

    Gilead delivered a solid first quarter with robust growth in its base business, particularly HIV, despite headwinds from Medicare Part D redesign and competitive pressures in cell therapy. The company highlighted significant pipeline advancements, including positive Phase III data for Trodelvy and an anticipated FDA decision for lenacapavir for PrEP, positioning it for multiple potential launches and sustained top-line growth beyond 2025.

    Highlights

    5
    • Base business, excluding Veklury, grew 4% year-over-year.

    • HIV sales increased 6% year-over-year, with Biktarvy up 7%.

    • Livdelzi achieved $40 million in sales in its second full quarter, capturing 1/3 of the second-line PBC market.

    • Trodelvy's Phase III ASCENT-04 study showed statistically significant and clinically meaningful progression-free survival benefit in 1L PD-L1+ mTNBC.

    • Non-GAAP operating margin was 43%, reflecting strong expense discipline.

    Concerns

    4
    • Total product sales, including Veklury, were down 1% year-over-year due to fewer COVID-19 hospitalizations.

    • Trodelvy sales were down 5% year-over-year and 17% sequentially due to inventory dynamics and lower average realized price.

    • Cell therapy sales were down 3% year-over-year and 5% sequentially, driven by accelerating competitive headwinds, particularly for Tecartus (down 22% YoY).

    • HIV sales were impacted by Medicare Part D redesign, obscuring demand-led volume growth and resulting in flat reported HIV sales expected for FY25.

    Guidance & targets

    15
    CategoryTargetConfidence
    Full-year Total Product Sales
    $28.2 billion to $28.6 billion
    high materiality
    High
    Full-year Product Sales excluding Veklury
    $26.8 billion to $27.2 billion
    high materiality
    High
    Full-year HIV Sales
    approximately flat compared to 2024
    high materiality
    High
    Full-year Veklury Sales
    approximately $1.4 billion
    medium materiality
    High
    Full-year Product Gross Margin (non-GAAP)
    85% to 86%
    medium materiality
    High
    Full-year R&D Expenses (non-GAAP)
    roughly flat from 2024
    medium materiality
    High
    Full-year Acquired IPR&D
    approximately $400 million
    medium materiality
    High
    Full-year SG&A Expenses
    decline by a high single-digit percentage compared to 2024
    medium materiality
    High
    Full-year Operating Income
    $12.7 billion to $13.2 billion
    high materiality
    High
    Full-year Effective Tax Rate
    approximately 19%
    medium materiality
    High
    Full-year Diluted EPS (non-GAAP)
    $7.70 to $8.10
    high materiality
    High
    Lenacapavir for PrEP Launch
    immediately following June 19 PDUFA date
    high materiality
    High
    Anito-cel Launch
    late-line relapsed/refractory multiple myeloma in 2026
    medium materiality
    Medium
    Trodelvy Launch in 1L mTNBC
    2026
    medium materiality
    Medium
    Once yearly lenacapavir for HIV prevention Phase III study initiation
    second half of this year
    low materiality
    High

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    HIV
    Driven by higher average realized price and higher demand, offset by Q1 seasonality and Medicare Part D redesign. Biktarvy increased U.S. market share. Descovy growth driven by broader awareness, growing unrestricted access, and associated pricing favorability.
    Biktarvy sales: $3.1 billionBiktarvy growth YoY: 7%Biktarvy U.S. market share: 51%Descovy sales: $586 millionDescovy growth YoY: 38%U.S. PrEP market growth YoY: 16%Descovy PrEP market share: >40%
    $4.6 billion6%-16%
    Liver Disease
    Reflecting increased demand across PBC, HBV, and HDV, partially offset by lower average realized price for HCV products. Livdelzi shows continued early momentum in its launch.
    Livdelzi sales: $40 million
    $758 million3%5%
    Veklury
    Reflecting lower rates of COVID-19-related hospitalizations due to a milder winter season. Maintains consistently high share as standard of care.
    Share of treated hospitalized patients in U.S.: >60%
    $302 million-45%-10%
    Oncology (Trodelvy)
    Reflecting inventory dynamics and lower average realized price, partially offset by higher demand. Sequentially, primarily driven by inventory dynamics and lower demand. Remains leading regimen in second-line metastatic triple-negative breast cancer.
    $293 million-5%-17%
    Cell Therapy
    Reflecting accelerating competitive headwinds, notably outside the U.S. and more specifically for Tecartus. Yescarta growth driven by higher average realized price and increased rest of world demand. Tecartus impacted by increased in and out of cost competition.
    Yescarta sales: $386 millionYescarta growth YoY: 2%Tecartus sales: $78 millionTecartus growth YoY: -22%
    $464 million-3%-5%

    Operational metrics

    17
    Base business growth (excluding Veklury)
    4%year-over-year
    Q1 FY25

    Primarily driven by growth in HIV business.

    Non-GAAP Operating Margin
    43%
    Q1 FY25

    Highlighting ongoing commitment to operating expense discipline.

    Acquired IPR&D expenses
    $253 million
    Q1 FY25

    Primarily driven by the LEO Pharma STAT6 collaboration announced in January.

    R&D expenses
    down 5%year-over-year
    Q1 FY25

    Primarily due to lower clinical manufacturing activities.

    SG&A expenses
    down 6%year-over-year
    Q1 FY25

    Reflecting lower corporate expenses, partially offset by incremental selling and marketing spend in the United States.

    Dividends and Share Repurchases
    $1.7 billion
    Q1 FY25

    Amount returned to shareholders.

    Livdelzi market share
    1/3
    Q1 FY25

    Achieved in its second full quarter since launch, growing 10 points share in one quarter.

    Livdelzi commercial plan coverage
    >80%
    Q1 FY25

    Expected to grow to well above 90% in the coming months.

    Lenacapavir for PrEP access target
    75%
    initial 6 months

    Expected covered lives access within the first 6 months post-launch.

    Lenacapavir for PrEP access target
    90%
    12-month mark

    Expected peak covered lives access at the 12-month mark post-launch.

    U.S. PrEP patients
    400,000-450,000
    today

    Current estimate of individuals on PrEP in the U.S.

    HIV prescribers also prescribing PrEP
    75%
    today

    Proportion of HIV prescribers who also prescribe PrEP, representing the target for lenacapavir launch.

    Medicare Part D redesign total impact
    $1.1 billion
    FY25

    Total expected impact from Medicare Part D redesign.

    Medicare Part D redesign HIV-specific impact
    $900 million
    FY25

    Expected impact specific to the HIV business from Medicare Part D redesign.

    HIV business growth (excluding Part D redesign)
    9%year-over-year
    Q1 FY25

    Hypothetical growth rate if Medicare Part D redesign impact was excluded.

    Average corporate tax rate
    20%
    Q1 FY25

    Reflects substantial majority of intellectual property registered in the United States.

    R&D capital infrastructure in U.S.
    almost 100%
    Q1 FY25

    Gilead's R&D capital infrastructure is almost entirely in the U.S.

    Industry KPIs

    10
    MetricValueDetails
    EPS$1.81USD
    Gross margin85%%
    Debt leverageA-
    Tariff impactmanageable
    Revenue net sales$6.6 billionUSD
    Effective tax rate16%%
    Pricing price realizationhigher average realized price
    Regulatory approvals filingsConditional Marketing Authorization
    Therapeutic drug market share51%%
    Clinical trial efficacy safety dataclinically meaningful and statistically significant improvement

    Deals & partnerships

    1
    LEO PharmaSTAT6 collaboration

    Collaboration announced in January, driving acquired IPR&D expenses.

    Risks & headwinds

    5
    Medicare Part D RedesignFY25

    Expected $1.1 billion total impact for FY25, with approximately $900 million specific to HIV.

    Mitigation: Expect robust demand-led volume growth to be obscured, resulting in flat reported HIV sales for 2025, with a return to growth in 2026. Monitoring closely for potential offsetting positive impact later in the year, but not expecting material uptick in volume due to existing safety nets.

    Competitive Headwinds in Cell TherapyExpected to extend through 2025

    Cell therapy sales down 3% YoY; Tecartus sales down 22% YoY.

    Mitigation: Working to increase CAR T cost penetration, breaking down barriers to adoption in community settings, and raising awareness of data and benefits of earlier CAR T. Potential launch of anito-cel in multiple myeloma in 2026.

    Veklury Sales DeclineQ1 FY25 (milder winter season)

    Veklury sales down 45% YoY to $302 million.

    Mitigation: Expect Veklury's important role to continue despite variability in the path of the pandemic.

    Trodelvy Inventory DynamicsQ1 FY25

    Trodelvy sales down 5% YoY and 17% sequentially.

    Mitigation: Higher demand partially offsets. Positive ASCENT-04 data expected to further strengthen position and confidence for physicians.

    Indirect Tariff Impact2025

    Expected to increase some indirect costs (e.g., steel, lab supplies, chemicals, reagents).

    Mitigation: Expected to be manageable in 2025 due to disciplined expense management and potentially lighter FX headwinds. Absorbed into current guidance.

    What to watch in Q2 FY25

    5

    Lenacapavir for PrEP FDA Decision

    Next quarter (Q2 FY25)
    CurrentPDUFA date June 19, 2025
    TargetApproval and immediate U.S. launch

    Why it matters

    This is a major new product launch for HIV prevention, critical for future growth and diversification.

    In HIV, we are now only weeks away from the anticipated FDA decision on twice yearly lenacapavir for PrEP. We remain on track for the June 19 PDUFA date and the potential launch in the U.S. immediately following.

    Q&A highlights

    6

    How will commercial and Medicaid reimbursement, as well as guideline changes, impact the lenacapavir PrEP launch in the second half of the year?

    Johanna Mercier stated they expect approximately 75% access within the first six months post-launch, peaking at 90% within 12 months. Initial access will involve medical exceptions, but the transformative nature of lenacapavir positions them well for building access.

    We think about 75% or so access within the first 6 months to a peak covered lives at about 90% at a 12-month mark, and that's going to happen month after month and it's not -- doesn't all happen in a bolus.

    asked by Michael Yee · answered by Johanna Mercier

    3 min read7 chapters

    Detailed Narrative

    01

    Q1 Performance Highlights

    Gilead reported strong commercial and clinical execution in Q1 FY25. The base business, excluding Veklury, grew 4% year-over-year, primarily driven by HIV. Total product sales, however, saw a 1% decline year-over-year, mainly due to fewer COVID-19-related hospitalizations impacting Veklury sales. Despite these dynamics, the company achieved strong operating margins and earnings per share, underscoring its focus on expense management and business model leverage.

    02

    HIV Business Dynamics

    The HIV business delivered robust sales growth of 6% year-over-year, with Biktarvy sales increasing 7%. This growth was demand-led but partially offset by the anticipated headwinds from the Medicare Part D redesign. Descovy sales surged 38% year-over-year, fueled by higher average realized prices and increased demand, contributing to a 16% year-over-year growth in the U.S. PrEP market. The company expects flat reported HIV sales for FY25 due to Part D, with a return to growth in 2026.

    03

    Oncology Pipeline Progress

    Gilead announced positive Phase III ASCENT-04 study results for Trodelvy in combination with pembrolizumab for first-line PD-L1 positive metastatic triple-negative breast cancer. The study demonstrated a clinically meaningful and statistically significant improvement in progression-free survival. The company plans to present these data at a medical congress and file with global regulatory authorities. An update on the Phase III ASCENT-03 study for Trodelvy monotherapy in first-line mTNBC is also expected later this quarter.

    04

    Cell Therapy Performance and Outlook

    Cell therapy sales experienced a 3% year-over-year decline, primarily due to accelerating competitive headwinds, particularly for Tecartus, which saw a 22% year-over-year decrease. Yescarta sales, however, increased 2% year-over-year. Despite these challenges, Gilead remains optimistic about the future of cell therapy, with the potential launch of anito-cel in multiple myeloma in 2026 and upcoming presentations of early-stage data for next-generation CAR T products at ASCO.

    05

    Liver Disease and Other Launches

    Livdelzi continued its strong launch momentum, generating $40 million in sales in its second full quarter and capturing approximately one-third of the second-line PBC market. The European Commission granted conditional marketing authorization for Livdelzi in February, leading to a recent launch in Germany and planned expansion into other major European markets. The ongoing Phase III IDEAL trial for Livdelzi could potentially double the addressable patient population in PBC.

    06

    Lenacapavir for PrEP Launch Readiness

    With the anticipated FDA decision for lenacapavir for PrEP weeks away (June 19 PDUFA date), Gilead is fully prepared for a U.S. launch. The company expects to achieve approximately 75% access within the first six months and 90% within 12 months. Awareness among healthcare providers and the community is high, and Gilead has mobilized its field teams, nurse educators, and field reimbursement managers to ensure a seamless customer experience and support for reimbursement processes.

    07

    Capital Allocation and Financial Strength

    Gilead returned $1.7 billion to shareholders in Q1 FY25 through dividends and share repurchases, maintaining its disciplined capital allocation strategy. The company's financial strength was further recognized by S&P, which upgraded Gilead's long-term debt rating from BBB+ with a positive outlook to A- with a stable outlook, citing the outlook for its HIV franchise, steady revenue growth, and strong cash flow generation.

    AI-generated summary of the company’s earnings call. Not investment advice.